SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CPark who wrote (56127)5/2/2020 11:59:01 PM
From: idahoranch13 Recommendations

Recommended By
erippetoe
JJINV
rodneyh07

  Read Replies (2) of 63276
 
CPark, we’ll likely get fairly mature data from the 100 patient UT trial later this year, and we could hear some earlier data from the prostate cancer trial. Scott Tagawa is the lead researcher in the UT trial and he’s involved in the prostate trial and the primary completition date is in a month. clinicaltrials.gov
If we continue to see good responses in these two indications, we’ll be above 60 before we even get the other BC data.
Here is Scotts tweet after Trodelvy’s approval. He sounds a bit enthused to me.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News